102 filings
Page 5 of 6
8-K
386mt w76
15 May 17
Kadmon Provides Business Update and Reports First Quarter 2017 Financial Results
12:00am
8-K
8wkx 7sndmg9
4 Apr 17
Other Events
12:00am
8-K
fhwz1apkjd084qvdu3
3 Apr 17
Kadmon Announces Amendment to Credit Agreement and Related Warrants
12:00am
8-K
zknf9l
22 Mar 17
Kadmon Reports Upcoming Milestones and Fourth Quarter and Full Year 2016 Financial Results
12:00am
8-K/A
8nmpfzpi55zy
9 Mar 17
Entry into a Material Definitive Agreement
12:00am
8-K/A
etu16mwpl74ne
8 Mar 17
Entry into a Material Definitive Agreement
12:00am
8-K
suosyao gc0
8 Mar 17
Entry into a Material Definitive Agreement
12:00am
8-K
28rjanzcy j557in5l6w
17 Feb 17
Departure of Directors or Certain Officers
12:00am
8-K
qzfmbojm0uvcf4kb
20 Jan 17
Other Events
12:00am
8-K
n7fe 9444eu
18 Jan 17
Departure of Directors or Certain Officers
12:00am
8-K
9ubprftxn0of7ca6qsgf
6 Jan 17
Departure of Directors or Certain Officers
12:00am
8-K
ddwpv1
6 Dec 16
Kadmon Presents Encouraging Data on Tesevatinib in EGFR-Mutated Non-Small Cell Lung Cancer with Brain Metastases and/or Leptomeningeal Metastases
12:00am
8-K
swwmkjdstcr1v2j54
5 Dec 16
Other Events
12:00am
8-K
uaj3am
21 Nov 16
Kadmon to Present Additional Data Demonstrating Tesevatinib Safety for the Treatment of Polycystic Kidney Disease at ASN Kidney Week 2016
12:00am
8-K
rbw51w97wvf9og97r
9 Nov 16
Kadmon Provides Business Update and Reports Third Quarter 2016 Financial Results
12:00am
8-K
daa5xp6 78ec25
30 Sep 16
Other Events
12:00am
8-K
0oq2qochjxku9z
21 Sep 16
Other Events
12:00am
8-K
zprw9s khe5itckzmu
21 Sep 16
Other Events
12:00am
8-K
twjyv s5h0
13 Sep 16
Departure of Directors or Certain Officers
12:00am
8-K
wmqtoftw1r8ou9rp szj
7 Sep 16
Kadmon Reports Financial and Operational Results
12:00am